Over the course of the last decades, Brazil has experienced a significant increase in the occurrence of chronic diseases related to the aging of the population, such as cardiac pathologies, cancers and other neurodegenerative syndromes (Wang et. al., 2014). Recently, the federal government has stimulated the production of such medicines in Brazil - which requires a robust industrial park based on scientific and technological knowledge. This research aims at investigating the characteristics of the institutional outline being implemented in the country in order to develop research, technology and the manufacturing of therapeutic Monoclonal Antibodies. It proposes to analyze how the selected public and private entities (researchers, research institutions, biotech companies and hospitals) and the Public Policy (Science, Technology & Innovation Policy; National Health Policy and Industrial Policy] interfere in the advance of Biological Drugs. The idea is to discuss the potential of public policy in mobilizing different interests and engendering an institutional environment that can be favorable to the progress of the biopharmaceutical industry and health research in developing countries.